Noubar Afeyan, Director at Moderna, Inc. (MRNA), sold 27,800 shares at $109.70 ($3.1M) on 2024-05-01, disclosed to the SEC on 2024-05-03.
Scheduled sale ($3.1M) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $109.70 | 3,982 | $437K | 14.2% |
| 2 | $109.70 | 3,982 | $437K | 14.2% |
| 3 | $110.42 | 4,572 | $505K | 16.4% |
| 4 | $110.42 | 4,572 | $505K | 16.4% |
| 5 | $111.55 | 4,246 | $474K | 15.4% |
| 6 | $111.55 | 4,246 |
| $474K |
| 15.4% |
| 7 | $112.77 | 1,500 | $169K | 5.5% |
| 8 | $113.40 | 700 | $79K | 2.6% |
| Total | $110.76 avg | 27,800 | $3.1M | 100% |
| Filing → |
| MRNA | SELL | 2025-12-15 | $1.4M | — | Filing → |
| MRNA | SELL | 2024-08-02 | $3.6M | — | Filing → |
| MRNA | SELL | 2024-07-26 | $2.9M | — | Filing → |